TherapeuticsMD Balance Sheet Health
Financial Health criteria checks 4/6
TherapeuticsMD has a total shareholder equity of $27.1M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $39.6M and $12.5M respectively.
Key information
0%
Debt to equity ratio
US$0
Debt
Interest coverage ratio | n/a |
Cash | US$5.05m |
Equity | US$27.09m |
Total liabilities | US$12.46m |
Total assets | US$39.55m |
Recent financial health updates
Recent updates
TherapeuticsMD raises $7M in private placement
Oct 03TherapeuticsMD appoints interim co-CEOs
Sep 12Therapeutics MD Q2 Earnings Preview
Aug 12TherapeuticsMD receives $15M equity investment from Rubric Capital
Aug 01TherapeuticsMD jumps 12% as top investor discloses insider purchase
Jul 19TherapeuticsMD plunges 42% as merger agreement ends
Jul 13TherapeuticsMD risks bankruptcy as EW Healthcare extends tender offer for acquisition
Jul 06TherapeuticsMD: Privatization Deal Expected To Meet With Shareholder Pushback
Jun 16TherapeuticsMD: Looking For A Potential Turnaround After Divesting VitaCare Business
Mar 14TherapeuticsMD: Time For Bulls To Take A Contrarian Approach
Oct 22TherapeuticsMD: The Long Road To Profitability
Jul 08TherapeuticsMD drops 3% despite consensus beating Q1 results
May 06TherapeuticsMD, Inc. (NASDAQ:TXMD): Are Analysts Optimistic?
Feb 24TherapeuticsMD: Annovera May Save The Day
Feb 04TherapeuticsMD, Inc. (NASDAQ:TXMD) Analysts Are More Bearish Than They Used To Be
Jan 29What Type Of Shareholders Make Up TherapeuticsMD, Inc.'s (NASDAQ:TXMD) Share Registry?
Jan 27Have Insiders Been Buying TherapeuticsMD, Inc. (NASDAQ:TXMD) Shares?
Dec 30TherapeuticsMD (NASDAQ:TXMD) Share Prices Have Dropped 87% In The Last Five Years
Dec 09TherapeuticsMD: Q3 Report Reveals Strong Rebound And Bolsters Commercial Outlook
Nov 25Therapeutics MD EPS beats by $0.01, beats on revenue
Nov 09Financial Position Analysis
Short Term Liabilities: TXMD's short term assets ($12.2M) exceed its short term liabilities ($6.0M).
Long Term Liabilities: TXMD's short term assets ($12.2M) exceed its long term liabilities ($6.5M).
Debt to Equity History and Analysis
Debt Level: TXMD is debt free.
Reducing Debt: TXMD currently has no debt however we can't compare to 5 years ago as we have no data for that period.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: Insufficient data to determine if TXMD has enough cash runway based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if TXMD has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.
Discover healthy companies
Company Analysis and Financial Data Status
Data | Last Updated (UTC time) |
---|---|
Company Analysis | 2025/01/10 11:31 |
End of Day Share Price | 2025/01/10 00:00 |
Earnings | 2024/09/30 |
Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package | Data | Timeframe | Example US Source * |
---|---|---|---|
Company Financials | 10 years |
| |
Analyst Consensus Estimates | +3 years |
|
|
Market Prices | 30 years |
| |
Ownership | 10 years |
| |
Management | 10 years |
| |
Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
TherapeuticsMD, Inc. is covered by 18 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst | Institution |
---|---|
John Tanner | Cantor Fitzgerald & Co. |
Robert Labick | CJS Securities, Inc. |
Esther Rajavelu | Deutsche Bank |